Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques
Gunter Almer, Karin Wernig, Matthias Saba-Lepek, Samih Haj-Yahya, Johannes Rattenberger, Julian Wagner, Kerstin Gradauer, Daniela Frascione, Georg Pabst, Gerd Leitinger, Harald Mangge, Andreas Zimmer, Ruth Prassl, Gunter Almer, Karin Wernig, Matthias Saba-Lepek, Samih Haj-Yahya, Johannes Rattenberger, Julian Wagner, Kerstin Gradauer, Daniela Frascione, Georg Pabst, Gerd Leitinger, Harald Mangge, Andreas Zimmer, Ruth Prassl
Abstract
Background: Atherosclerosis is a leading cause of mortality in the Western world, and plaque diagnosis is still a challenge in cardiovascular medicine. The main focus of this study was to make atherosclerotic plaques visible using targeted nanoparticles for improved imaging. Today various biomarkers are known to be involved in the pathophysiologic scenario of atherosclerotic plaques. One promising new candidate is the globular domain of the adipocytokine adiponectin (gAd), which was used as a targeting sequence in this study.
Methods: gAd was coupled to two different types of nanoparticles, namely protamine-oligonucleotide nanoparticles, known as proticles, and sterically stabilized liposomes. Both gAd-targeted nanoparticles were investigated for their potency to characterize critical scenarios within early and advanced atherosclerotic plaque lesions using an atherosclerotic mouse model. Aortic tissue from wild type and apolipoprotein E-deficient mice, both fed a high-fat diet, were stained with either fluorescent-labeled gAd or gAd-coupled nanoparticles. Ex vivo imaging was performed using confocal laser scanning microscopy.
Results: gAd-targeted sterically stabilized liposomes generated a strong signal by accumulating at the surface of atherosclerotic plaques, while gAd-targeted proticles became internalized and showed more spotted plaque staining.
Conclusion: Our results offer a promising perspective for enhanced in vivo imaging using gAd-targeted nanoparticles. By means of nanoparticles, a higher payload of signal emitting molecules could be transported to atherosclerotic plaques. Additionally, the opportunity is opened up to visualize different regions in the plaque scenario, depending on the nature of the nanoparticle used.
Keywords: adiponectin; atherosclerosis; liposomes; molecular imaging; nanoparticles; proticles.
Figures
References
- Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002;13(1):51–59.
- Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004;344(1–2):1–12.
- Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–451.
- Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005;5(2):129–134.
- Fang X, Sweeney G. Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Trans. 2006;34(Pt 5):798–801.
- Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98(4):2005–2010.
- Bruce CR, Mertz VA, Heigenhauser GJ, Dyck DJ. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes. 2005;54(11):3154–3160.
- Palanivel R, Fang X, Park M, et al. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res. 2007;75(1):148–157.
- Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278(4):2461–2468.
- Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278(45):45021–45026.
- Li CJ, Sun HW, Zhu FL, et al. Local adiponectin treatment reduces atherosclerotic plaque size in rabbits. J Endocrinol. 2007;193(1):137–145.
- Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32(2):47–50.
- Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057–1063.
- Junghans M, Kreuter J, Zimmer A. Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res. 2000;28(10):E45.
- Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm. 2005;59(3):419–429.
- Weyermann J, Lochmann D, Georgens C, Zimmer A. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: Cellular uptake and effect. Eur J Pharm Biopharm. 2005;59(3):431–438.
- Wernig K, Griesbacher M, Andreae F, et al. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release. 2008;130(2):192–198.
- Kratzer I, Wernig K, Panzenboeck U, et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release. 2007;117(3):301–311.
- Kerkmann M, Lochmann D, Weyermann J, et al. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides. 2006;16(4):313–322.
- Briley-Saebo KC, Mulder WJ, Mani V, et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: Current imaging strategies and molecular imaging probes. J Magn Reson Imaging. 2007;26(3):460–479.
- Erdogan S. Liposomal nanocarriers for tumor imaging. J Biomed Nanotechnol. 2009;5(2):141–150.
- Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in medical imaging: Probe design and applications. Arterioscler Thromb Vasc Biol. 2009;29(7):992–1000.
- Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.
- Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv. 2007;4(4):297–305.
- Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327(2):181–192.
- Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev. 1998;32(1–2):139–152.
- Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: Structural aspects for pulmonary delivery. Biochim Biophys Acta. 2007;1768(3):705–714.
- Starcher B. A ninhydrin-based assay to quantitate the total protein content of tissue samples. Anal Biochem. 2001;292(1):125–129.
- Sinn HJ, Schrenk HH, Friedrich EA, Via DP, Dresel HA. Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agent. Anal Biochem. 1988;170(1):186–192.
- Pabst G. Global properties of biomimetic membranes: Perspectives on molecular features. Biophys Rev Lett. 2006;1(1):57–84.
- Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging. 2007;25(4):667–680.
- Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol. 2009;29(7):983–991.
- Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451(7181):953–957.
- Lindsay AC, Choudhury RP. Form to function: Current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov. 2008;7(6):517–529.
- Nahrendorf M, Sosnovik DE, Weissleder R. MR-optical imaging of cardiovascular molecular targets. Basic Res Cardiol. 2008;103(2):87–94.
- Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J. 2010;74(2):213–220.
- Woollard KJ, Geissmann F. Monocytes in atherosclerosis: Subsets and functions. Nat Rev Cardiol. 2010;7(2):77–86.
- Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010;17(36):4511–4520.
- Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res. 1968;9(3):310–318.
- Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta. 1995;1234(1):74–80.
- Uppal R, Caravan P. Targeted probes for cardiovascular MR Imaging. Future Med Chem. 2(3):451–470. 1;
- Voinea M, Simionescu M. Designing of ‘intelligent’ liposomes for efficient delivery of drugs. J Cell Mol Med. 2002;6(4):465–474.
- Ortner A, Wernig K, Kaisler R, et al. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J Drug Target. 2010;18(6):457–467.
- Parker JC. Transport and distribution of charged macromolecules in lungs. Adv Microcirc. 1987;(13):150–159.
- Chono S, Tauchi Y, Morimoto K. Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice. Drug Dev Ind Pharm. 2006;32(1):125–135.
- Maiseyeu A, Mihai G, Kampfrath T, et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J Lipid Res. 2009;50(11):2157–2163.
- Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J Control Release. 2002;79(1–3):29–40.
- Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 1998;46(3):255–263.
- Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The endothelial glycocalyx: A potential barrier between health and vascular disease. Curr Opin Lipidol. 2005;16(5):507–511.
- Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr. 1995;15:495–518.
- Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117(1):195–205.
Source: PubMed